Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5809764 | 0.92 | AKR1C3 (0.41) | AKR1C3AKR1C2PTGS2PLA2G4APTGS1 | |
| SCHEMBL6425189 | 0.92 | PTGS2 (0.46) | AKR1C3AKR1C2PTGS2PTGS1TP53 | |
| SCHEMBL5811222 | 0.91 | AKR1C3 (0.48) | AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL5558854 | 0.90 | AKR1C3 (0.40) | AKR1C3AKR1C2PTGS2PLA2G4APTGS1 | |
| SCHEMBL5560732 | 0.89 | AKR1C3 (0.42) | AKR1C3AKR1C2PTGS2PLA2G4APTGS1 | |
| SCHEMBL5554281 | 0.89 | AKR1C3 (0.41) | AKR1C3AKR1C2PTGS2PLA2G4APTGS1 | |
| SCHEMBL5556085 | 0.89 | AKR1C3 (0.41) | AKR1C3AKR1C2PTGS2PLA2G4APTGS1 | |
| SCHEMBL5558893 | 0.87 | AKR1C3 (0.45) | AKR1C3AKR1C2PTGS2PLA2G4APTGS1 | |
| SCHEMBL5807935 | 0.85 | PTGS2 (0.42) | AKR1C3AKR1C2PTGS2 | |
| SCHEMBL6426417 | 0.85 | AKR1C3 (0.45) | AKR1C3AKR1C2PTGS2PLA2G4APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643961-A4 | COX-2 AND FAAH INHIBITORS | MICROBIA INC (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006050120-A2 | SYNTHESIS OF COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-1643961-A2 | COX-2 AND FAAH INHIBITORS | Microbia, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050032747-A1 | COX-2 and FAAH inhibitors | POLYMER CONCEPTS TECHNOLOGIES PBY, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005002525-A2 | COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032747-A1 | COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGS2 | AKR1C3 585/4885AKR1C2 342/4885PTGS2 3/4885 |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | AKR1C3 577/4885AKR1C2 563/4885PTGS2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.